Close Menu

circulating tumor DNA

The company is developing liquid biopsy tests to detect disease recurrence and drug resistance, but does not yet have a specific plan for its first commercial assay.

The company is embarking on a study of up to 2,000 patients to compare its tissue-based targeted sequencing assay with its cell-free DNA test.

Clinical applications for the approach are already at hand, and are poised to expand as companies solidify the clinical validity and utility data behind their platforms.

Last year, company founders published a paper in which they presented CAPP-Seq, a sensitive and inexpensive method for detecting and profiling ctDNA from cancer patients.

The company said it is shifting focus from demonstrating clinical validity to proving its test can improve patient care and outcomes.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

CAPP Medical, based in Palo Alto, Calif., was founded in October 2013 by Stanford University oncologists and "industry veterans."

The results need to be validated but demonstrate the clinical utility of a more sensitive screen for detecting minimal residual disease.

The partners hope to demonstrate the clinical utility of Biocept's liquid biopsy technology in improving the care of NSCLC patients.

With the support of the new funds, the company hopes to launch its NeoLiquid test by the end of this year after completing beta tests.

Pages

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.